Clinical Trials Browser

Phase 1/2 × Interventional × Anlotinib × Clear all

NCT04803851 2023-06-22

Anlotinib Plus Anti-PD-1 Antibody AK105 for Advanced Pancreatic Cancer

Phase 1/2 Unknown

Gastrointestinal

Anlotinib